• Notorious RSV

  • Jul 2 2024
  • Length: 17 mins
  • Podcast

Notorious RSV By cover art

Notorious RSV

Listen for free

View show details

  • Summary

  • Last year, the healthcare system faced a surge of COVID, influenza, and RSV cases, filling hospitals with children in critical condition. Despite the introduction of a promising new RSV treatment, nirsevimab, its rollout was hampered by supply shortages and logistical challenges. Daniel Dodson, MD, MS, a pediatric infectious disease specialist, explained that the limited supply required careful allocation to high-risk infants, leading to difficult decisions and impassioned pleas from caregivers.

    Resources:
    • Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals - Pediatric Pandemic Network
    • Nirsevimab Frequently Asked Questions - American Academy of Pediatrics
    • Nirsevimab for Prevention of RSV in Healthy Late -Preterm and Term Infants - The New England Journal of Medicine
    • Immunizations to Protect Infants - CDC
    Show more Show less
activate_primeday_promo_in_buybox_DT
Physical Illness & Disease Hygiene & Healthy Living History Social Sciences Personal Success
Show more Show less

What listeners say about Notorious RSV

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available